Print this article
- 05/24/2021

Vytrus increases its sales by 40% and triples its EBITDA in 2020

HPC Today

Tags:

Vytrus Biotech, the company specialised in active ingredients derived from plant stem cells for the cosmetic industry, has broken its own record and turnover forecasts, reaching 1.7 million euros at the end of 2020. The company thus reaches a milestone in its trajectory: the operational break even.

This milestone, which classifies Vytrus as a profitable company, represents a challenge in the whirlwind of the pandemic year and reflects the company’s strong position in front of its shareholders and the market. Once the breakeven has been reached, the industrial biotechnology company will focus on continuing the international expansion of the business and scaling the profitability obtained in 2021.

According to Albert Jané, CEO and co-founder of Vytrus: ‘We are very happy with the great results obtained in 2020, especially since the exceptional situation has required a huge effort from each person in our team. Despite the difficult situation, we came out very strengthened as a team and we hope this achievement to boost our growth in the coming years’.

The audited annual accounts of Vytrus for 2020 reflect an increase in its EBITDA (operating profit) of by 20

The results of the biotech company represent an increase of 4

The beginning of the pandemic meant an environment of uncertainty and a certain impact on the company, which quickly rallied and maintained its growth rate from month to month, thanks to the effort and dedication of a highly qualified and committed team. A round year marked by its record in turnover and EBITDA, the Ecovadis Silver Medal recognition (positive evaluation of its good sustainability practices, together with the 2

www.vytrus.com